Drug patent litigation isn’t just about the molecule—it’s about the design choices around it.
In the last decade, “design-around” has evolved from a legal strategy into a core product-development discipline. And nowhere is that more true than in the …

Pharma has a $300 billion question it can’t afford to misread: is it getting a patent “term restoration” or a patent “term adjustment”?
On paper, the difference sounds technical. In practice, it can determine whether a blockbuster’s exclusivity window …

Pharma executives don’t lose in court—they lose in the calendar.
If you operate in Eurasia, the real risk isn’t just unfamiliar regulators or complex filings. It’s timing: when patents are published, when exclusivities attach, when enforcement become…

Pharmaceutical patent strategy is often treated like a binary choice: fight every case, or give up and move on. But the real world is messier—and more expensive.
In a recent piece from DrugPatentWatch, the “cut, keep, or cash” decision matrix reframes …

The clock is already ticking—so why are so many commercial market access teams still waiting for the patent to expire?
In pharma, timing isn’t a detail. It’s the business model.
Drug patent cliffs don’t just change pricing—they reshape leverage, contra…

Pharma companies don’t lose deals because their science is weak.
They lose them because the legal risk was discovered too late.
That’s the uncomfortable truth behind “Freedom to Operate” (FTO) analysis—and why the best teams treat it like a product mil…

Most pharma buyers treat Paragraph IV diligence like a checkbox. That’s why they keep getting surprised.
If you buy drugs—or advise the teams that do—you already know the headline risk: Paragraph IV filings can flip a deal from “routine” to “rework” fa…

Drug patents in Asia-Pacific: the protection you think you have vs. the protection you actually get
If you’re underwriting a pipeline, pricing a launch, or modeling generic entry in Asia-Pacific, here’s the uncomfortable truth: “patent protection” is n…